Insulin human is under clinical development by Aerami Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Insulin human’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Insulin human overview

AER-501 is under development for the treatment of type 1 diabetes and type 2 diabetes. It is is the drug-device combination. The drug candidate is administered through inhalational route and formulated as solution. Insulin is a natural hormone made by the pancreas that controls the level of the sugar glucose in the blood. It acts by targeting insulin receptor. It was also under development for the treatment of chronic obstructive pulmonary disease and asthma.

Aerami Therapeutics overview

Aerami Therapeutics (Aerami), formerly Aerami Therapeutics Inc, is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company provides a product pipeline such as AER-901 – Inhaled Imatinib, AER-601 – Soft-mist Inhaled Exenatide and AER-501 – Soft-mist Inhaled Insulin among others. It has completed Phase II clinical trials and is in preparation for pivotal development. Aerami offers AER-501 designed to control prandial blood sugar in adults with diabetes without the need for injections. The company develops liquid formulations of insulin based on the vibrating mesh micropump technology developed and commercialized by Aerogen. Aerami is headquartered in Durham, North Carolina, US.

For a complete picture of Insulin human’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.